Market Overview

Credit Suisse Downgrades United Therapeutics To Underperform


Analysts at Credit Suisse downgraded United Therapeutics (NASDAQ: UTHR) from Neutral to Underperform.

The price target for United Therapeutics has been raised from $100 to $120.

United Therapeutics shares have surged 44.98% over the past 52 weeks, while the S&P 500 index has gained 14.12% in the same period.

United Therapeutics' shares fell 2.51% to close at $131.42 yesterday.

Latest Ratings for UTHR

Mar 2019BarclaysMaintainsUnderweightUnderweight
Nov 2018Credit SuisseMaintainsUnderperformUnderperform
Nov 2018JP MorganMaintainsNeutralNeutral

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: Credit SuisseDowngrades Analyst Ratings


Related Articles (UTHR)

View Comments and Join the Discussion!

Latest Ratings

VNTRRBC CapitalUpgrades0.0
TCBICompass PointDowngrades0.0
AEPMorgan StanleyDowngrades0.0
QCOMDZ BankUpgrades0.0
PEPGoldman SachsUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: KBR Unveils Plan to Reorganize Into Three New Businesses

UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak